Abstract 96P
Background
To compare the doublet gemcitabine and cisplatin which is a standard of care in locally advanced or metastatic gall bladder cancer to a triplet gemcitabine, cisplatin and nab paclitaxel regime which has shown promising results in a single arm phase II study.
Methods
A total of 60 patients with locally advanced or metastatic gall bladder cancer were randomized 30 in each arm after imaging [contrast enhanced CT scan of chest, abdomen, and pelvis / MRI abdomen and pelvis with CECT chest /whole-body PET CT scan] and biopsy. Arm A received two drugs gemcitabine 1000mg/m2 i.v and cisplatin 25mg/m2 i.v on Day1 and Day8 of 21-day cycle and arm B received three drugs gemcitabine, 1000 mg/m2 , cisplatin, 25 mg/m2 , and nab-paclitaxel, 125 mg/m2 , on days 1 and 8 of 21-day cycle. Evaluation was done post 3 and 6 cycles of chemotherapy. Then patients were followed up every 6 months for 2 years period for assessment of primary and secondary endpoints of the study.
Results
The combination of gemcitabine and cisplatin (arm A) showed an overall radiological response rate (complete response and partial response) of 13.3% while it was 61.9 % in patients who received gemcitabine, cisplatin, and nab-paclitaxel. This difference was statistically significant with a p-value of 0.004. The median progression-free survival for the patients who received gemcitabine and cisplatin was 4.5 months (95% CI, 4.0-4.9) vs 7.6 months (95% CI, 3.9-11.2) for the patients who were treated with gemcitabine, cisplatin, and nab-paclitaxel. This difference was statistically significant with a p-value of ≤ 0.05. The median overall survival for the doublet was 9.2 months (95% CI 2.6-15.7) vs not reached for the patients who were treated with gemcitabine, cisplatin, and nab-paclitaxel. There was no increase in grade 3 adverse events with the addition of nab-paclitaxel.
Conclusions
To conclude, our study showed that the triplet chemotherapy with gemcitabine and cisplatin and nab-paclitaxel was significantly better in terms of overall response rate, and median progression-free survival with a longer follow up needed to comment on median overall survival.
Clinical trial identification
CTRI/2021/09/036362.
Editorial acknowledgement
Legal entity responsible for the study
C. Khatri.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17